Souhaitez-vous accéder aux communiqués récents ?

TAMPA, Fla. and LONDON, March 18, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splice...

TAMPA, Fla. and LONDON, March 17, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splice...

Data demonstrating superior selectivity, safety and pharmacokinetics of RGT-0474060 were presented at the 21st Annual Huntington’s Disease Therapeutics Conference (CHDI) being held this week in Palm...

Chicago, Jan. 28, 2026 (GLOBE NEWSWIRE) -- The global high-speed camera market was valued at 4,060.3 million in 2024 and is expected to reach US$ 7,036.5 million by 2033, growing at a CAGR of 6.3%...

Chicago, Jan. 27, 2026 (GLOBE NEWSWIRE) -- The global cell penetrating peptide market was valued at 2.16 billion in 2024 and is expected to reach US$ 8.12 billion by 2033, growing at a CAGR of...

Biosplice Announces First Patient Dosed in Investigator‑Initiated Phase 1 Clinical Trial of Cirtuvivint and Olaparib in Ovarian Cancer

Anti-tumor activity was observed in heavily pretreated mCRPC patients across all dose cohorts; in 22 patients who completed at least 2 cycles of therapy, 59% achieved PSA50 response and 32% achieved...

Data highlights ability of Akari’s ADC payload, PH1, to suppress the levels of the AR-V7 receptor that is responsible for driving hormone refractory prostate cancer progression No current therapies...

Multicenter study sponsored by the National Cancer Institute

NEW YORK, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Berry Street, an AI-powered nutrition therapy platform, today announced three strategic appointments: Richard Fu has joined as the company’s first Chief...